Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
Treatment of Acute Sinusitis
- Conditions
- Acute Respiratory InfectionsAcute Rhinosinusitis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 172
- Registration Number
- NCT00377403
- Locations
- 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States
Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia
- Conditions
- Pneumonia
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Boston Medical Center
- Registration Number
- NCT00227331
Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation
- Conditions
- LymphomaLymphoma, Non-Hodgkin
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-26
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 200
- Registration Number
- NCT00154440
- Locations
- 🇩🇪
Institute for Pathology, Bayreuth, Bavaria, Germany
🇩🇪Dept. for Radiation Therapy & Radiooncology, University Hospital, Germany, Saxonia, Germany
🇩🇪Med. Dept. I, Gastroenterology, Dresden, Saxonia, Germany
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
- Conditions
- Helicobacter InfectionsGastritisGastric UlcerDuodenal Ulcer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Hamamatsu University
- Target Recruit Count
- 296
- Registration Number
- NCT00149084
- Locations
- 🇯🇵
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Guidelines for Acute Sinusitis
- Conditions
- Sinusitis
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2008-05-20
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 240
- Registration Number
- NCT00132275
- Locations
- 🇺🇸
University of Pittsburgh/Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Efficacy of Single Versus Double Dose of Oral Amoxicillin for Non-Severe Pneumonia in Children
- Conditions
- Pneumonia
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2005-09-23
- Lead Sponsor
- ARI Research Cell
- Target Recruit Count
- 900
- Registration Number
- NCT00130013
- Locations
- 🇵🇰
ARI Research Cell, Children Hospital, Pakistan Institute of Medical Sciences, Islamabad, Capital, Pakistan
APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat
- Conditions
- Pharyngitis
- First Posted Date
- 2004-12-24
- Last Posted Date
- 2006-10-25
- Lead Sponsor
- Advancis Pharmaceutical Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00100126
- Locations
- 🇺🇸
Institute for Neuroscience Research, Salt Lake City, Utah, United States
APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat
- Conditions
- PharyngitisTonsillitis
- First Posted Date
- 2004-11-04
- Last Posted Date
- 2006-12-08
- Lead Sponsor
- Advancis Pharmaceutical Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00095368
- Locations
- 🇺🇸
Manford Gooch, MD, Salt Lake City, Utah, United States
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 96
- Registration Number
- NCT00003151
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom
🇬🇧Royal United Hospital, Bath, England, United Kingdom
🇬🇧Royal Free Hospital, Hampstead, London, England, United Kingdom
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00002682
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center Orlando, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.